Endologix to Present at the Canaccord Genuity 35th Annual Growth Conference

IRVINE, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Bob Mitchell, President, is scheduled to present at the Canaccord Genuity 35th Annual Growth Conference in Boston, MA.

Event: Canaccord Genuity 35th Annual Growth Conference
Date: Wednesday, August 12, 2015
Time: 2:00 pm ET / 11:00 am PT

An audio webcast of the Company's presentation at the conferencewill be available by visiting the investor relations section of Endologix's website at www.endologix.com. A replay of the presentation will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.

CONTACT: COMPANY CONTACT: Endologix, Inc. John McDermott, CEO Shelley Thunen, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020Source:Endologix